Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis | Zendy

Ludwig Kappos | Zendy; Heinz Wiendl | Zendy; Krzysztof Selmaj | Zendy; Douglas L. Arnold | Zendy; Eva Havrdová | Zendy; Alexey Boyко | Zendy; Michael D. Kaufman | Zendy; John Rose | Zendy; Steven J. Greenberg | Zendy; Marianne T. Sweetser | Zendy; Katherine Riester | Zendy; Gilmore O’Neill | Zendy; Jacob Elkins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Author(s) -

Ludwig Kappos,

Heinz Wiendl,

Krzysztof Selmaj,

Douglas L. Arnold,

Eva Havrdová,

Alexey Boyко,

Michael D. Kaufman,

John Rose,

Steven J. Greenberg,

Marianne T. Sweetser,

Katherine Riester,

Gilmore O’Neill,

Jacob Elkins

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1501481

Subject(s) - daclizumab , medicine , multiple sclerosis , monoclonal antibody , immunology , pathogenesis , interferon beta , beta (programming language) , receptor , il 2 receptor , antibody , immune system , t cell , computer science , programming language

Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research